Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma
NCT07835035Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rimegepant in urothelial carcinoma (UC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Incidence of dose-limiting toxicities at 14 days and Recommended Phase 2 dose at 8 months. Started Jul 2026; status: recruiting.
02
Drugs
rimegepant
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07835035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07835035.